AR112781A2 - PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - Google Patents
PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSInfo
- Publication number
- AR112781A2 AR112781A2 ARP180102260A ARP180102260A AR112781A2 AR 112781 A2 AR112781 A2 AR 112781A2 AR P180102260 A ARP180102260 A AR P180102260A AR P180102260 A ARP180102260 A AR P180102260A AR 112781 A2 AR112781 A2 AR 112781A2
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- peptide
- cells
- combination
- mhc
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se relaciona con péptidos, proteínas, ácidos nucleicos y células para su uso en métodos inmunoterapéuticos. En particular, la presente se relaciona con inmunoterapia para el cáncer. Se relaciona además con epitopes de péptidos de células T asociados con tumores, solos o en combinación con otros péptidos asociados con tumores que pueden, por ejemplo, servir como ingredientes farmacéuticos activos de composiciones para vacunas que estimulan la respuesta inmune antitumoral o para estimular células T ex vivo y transferirlas a pacientes. Los péptidos unidos a moléculas del complejo de histocompatibilidad principal (MHC) o los péptidos como tales también pueden ser el blanco de anticuerpos, receptores de células T solubles y otras moléculas de unión. Reivindicación 2: El péptido de acuerdo con la reivindicación 1, caracterizado porque dicho péptido tiene la capacidad de unirse a una molécula de MHC de clase I o II, y en donde dicho péptido, cuando se une a dicha MHC, es capaz de ser reconocido por las células T CD4 y/o CD8.This document relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, this is related to immunotherapy for cancer. It is further related to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can, for example, serve as active pharmaceutical ingredients in vaccine compositions that stimulate the antitumor immune response or to stimulate T cells ex vivo and transfer them to patients. Peptides bound to major histocompatibility complex (MHC) molecules or peptides as such can also be targeted by antibodies, soluble T-cell receptors, and other binding molecules. Claim 2: The peptide according to claim 1, characterized in that said peptide has the ability to bind to a class I or II MHC molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and / or CD8 T cells.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139189P | 2015-03-27 | 2015-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112781A2 true AR112781A2 (en) | 2019-12-11 |
Family
ID=59256464
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Country Status (1)
| Country | Link |
|---|---|
| AR (7) | AR104113A1 (en) |
-
2016
- 2016-03-28 AR ARP160100818A patent/AR104113A1/en unknown
-
2018
- 2018-08-08 AR ARP180102260A patent/AR112781A2/en unknown
-
2021
- 2021-04-09 AR ARP210100947A patent/AR121810A2/en unknown
- 2021-04-09 AR ARP210100945A patent/AR121809A2/en unknown
- 2021-04-09 AR ARP210100948A patent/AR121811A2/en unknown
- 2021-04-09 AR ARP210100949A patent/AR121812A2/en unknown
- 2021-09-13 AR ARP210102531A patent/AR123493A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR121810A2 (en) | 2022-07-13 |
| AR123493A2 (en) | 2022-12-07 |
| AR121812A2 (en) | 2022-07-13 |
| AR104113A1 (en) | 2017-06-28 |
| AR121809A2 (en) | 2022-07-13 |
| AR121811A2 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127119A2 (en) | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | |
| CL2023001346A1 (en) | Use of peptides in immunotherapy against small cell lung cancer and others. | |
| CO2018002202A2 (en) | Peptides and combinations of peptides for immunotherapy against prostate cancer and other types of cancer | |
| CO2018000252A2 (en) | Peptides and combinations of peptides for immunotherapy against epithelial ovarian cancer and other types of cancer | |
| CO2017008902A2 (en) | Peptides and new combinations of peptides for immunotherapy against lung cancer, including amicrocytic lung cancer and other types of cancer | |
| PE20181164A1 (en) | NEW PEPTIDES, PEPTIDE COMBINATIONS AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCERS | |
| PE20180174A1 (en) | NEW CELLULAR EPITOPES AND NEW COMBINATIONS OF CELLULAR EPITOPS FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER TYPES OF CANCER | |
| CR20180001A (en) | NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER. | |
| CR20180191A (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST MICROCHATIC LUNG CANCER AND OTHER TYPES OF CANCER | |
| CO2017012891A2 (en) | Peptides and combinations of peptides for immunotherapy against ovarian cancer and other types of cancer | |
| CR20180245A (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TYPES OF CANCER | |
| PE20181075A1 (en) | NEW PEPTICS AND NEW PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) AND OTHER TYPES OF CANCERS | |
| CR20180460A (en) | TREATMENT AGAINST UTERUS CANCER | |
| CO2018000245A2 (en) | Peptides and combinations of peptides for immunotherapy against pancreatic cancer and other types of cancer | |
| CR20220115A (en) | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (Div. 2017-522) | |
| CO2018012914A2 (en) | Peptides and combination of peptides as targets and for immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer | |
| CO2019012077A2 (en) | Peptides and combinations thereof for use in immunotherapy against various types of cancer | |
| CR20170579A (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGIC CANCER AND OTHER CANCER. | |
| CO2018012294A2 (en) | Immunotherapy against melanoma and other types of cancer | |
| CL2021000177A1 (en) | Peptides, peptide combinations, cells and kits for use in cancer immunotherapy (divisional application no. 201802360) | |
| CO2018004869A2 (en) | Peptides and combination of peptides for immunotherapy against various types of cancer | |
| CL2017002346A1 (en) | New peptides and new combination of peptides for use in immunotherapy against pancreatic cancer and other types of cancer | |
| CO2017010830A2 (en) | Peptides and combinations of peptides and supports | |
| CO2018000247A2 (en) | New cell epitopes and new combinations of cell epitopes for use in the immunotherapy of myeloma and other types of cancer | |
| CL2021001010A1 (en) | Peptides and peptide combinations for use in immunotherapy against small cell lung cancer and other types of cancer (divisional application no. 201800780) |